TRANSLATE

The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

pso logo
Brought to you by Scientific Education Support

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EADV 2023: Top abstracts in psoriasis and psoriatic arthritis

By Ella Dixon

Share:

Oct 10, 2023

To help navigate the exciting content being presented at the European Academy of Dermatology and venerology (EADV) 2023 Congress, we have provided recommendations for the top abstracts to look out for in psoriasis and psoriatic arthritis.

Psoriasis

6624

 

Efficacy and safety of ME3183 administered orally in subjects with moderate to severe plaque psoriasis: A multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 2a study

1732

Effect of high-dose subcutaneous spesolimab on skin manifestations: Results from the pivotal Effisayil 2 trial of flare prevention in generalized pustular psoriasis

3364

Deucravacitinib significantly improves symptoms and signs of psoriasis in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials

4506

A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: Efficacy of Overall and Scalp Psoriasis Responses from FRONTIER 1

3536

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, improves outcomes in plaque, generalized pustular, and erythrodermic psoriasis in Japan: results from the POETYK PSO-4 study

 

 

Psoriatic arthritis

2959

Bimekizumab efficacy and safety in patients with active psoriatic arthritis and psoriasis: 52-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies

1204

Long-term Efficacy of Guselkumab on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologicnaïve Patients With Psoriatic Arthritis

3319

Ixekizumab significantly improved quality of life and joint pain in patients with psoriatic arthritis, nail disease and DIP Involvement from SPIRIT-H2H

4041

Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial

4887

Early Oligoarticular Psoriatic Arthritis Responds to Treatment With Apremilast: Week 16 Results From FOREMOST – a Phase 4 Randomized Controlled Trial

EADV 2023 abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EADV 2023PsoriasisPsoriatic arthritis

Newsletter

Subscribe to get the best content delivered to your inbox